These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 1615580)
1. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor. Zhao X; van Steenbrugge GJ; Schröder FH Urol Res; 1992; 20(3):193-7. PubMed ID: 1615580 [TBL] [Abstract][Full Text] [Related]
2. The human prostatic carcinoma cell line LNCaP and its derivatives. An overview. van Steenbrugge GJ; Groen M; van Dongen JW; Bolt J; van der Korput H; Trapman J; Hasenson M; Horoszewicz J Urol Res; 1989; 17(2):71-7. PubMed ID: 2660395 [TBL] [Abstract][Full Text] [Related]
3. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response. Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667 [TBL] [Abstract][Full Text] [Related]
4. The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. van Steenbrugge GJ; van Uffelen CJ; Bolt J; Schröder FH J Steroid Biochem Mol Biol; 1991; 40(1-3):207-14. PubMed ID: 1958522 [TBL] [Abstract][Full Text] [Related]
5. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046 [TBL] [Abstract][Full Text] [Related]
6. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686 [TBL] [Abstract][Full Text] [Related]
7. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. Joly-Pharaboz MO; Soave MC; Nicolas B; Mebarki F; Renaud M; Foury O; Morel Y; Andre JG J Steroid Biochem Mol Biol; 1995 Oct; 55(1):67-76. PubMed ID: 7577722 [TBL] [Abstract][Full Text] [Related]
8. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349 [TBL] [Abstract][Full Text] [Related]
9. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592 [TBL] [Abstract][Full Text] [Related]
10. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids. Esquenet M; Swinnen JV; Heyns W; Verhoeven G J Steroid Biochem Mol Biol; 1997 Aug; 62(5-6):391-9. PubMed ID: 9449242 [TBL] [Abstract][Full Text] [Related]
11. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Zhao XY; Ly LH; Peehl DM; Feldman D Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780 [TBL] [Abstract][Full Text] [Related]
12. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Gunawardena K; Murray DK; Meikle AW Prostate; 2000 Sep; 44(4):287-95. PubMed ID: 10951493 [TBL] [Abstract][Full Text] [Related]
13. Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M; Dondi D; Moretti RM; Montagnani Marelli M; Pimpinelli F; Maggi R; Limonta P J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):107-11. PubMed ID: 8603030 [TBL] [Abstract][Full Text] [Related]
14. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells. Schatten H; Ripple M; Balczon R; Weindruch R; Chakrabarti A; Taylor M; Hueser CN J Cell Biochem; 2000 Jan; 76(3):463-77. PubMed ID: 10649443 [TBL] [Abstract][Full Text] [Related]
15. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Langeler EG; van Uffelen CJ; Blankenstein MA; van Steenbrugge GJ; Mulder E Prostate; 1993; 23(3):213-23. PubMed ID: 7694266 [TBL] [Abstract][Full Text] [Related]
16. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours. Maucher A; von Angerer E J Cancer Res Clin Oncol; 1993; 119(11):669-74. PubMed ID: 8349724 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of antiproliferative effects of interleukin-1beta and tumor necrosis factor-alpha on human prostate cancer LNCaP cells by coculture with normal fibroblasts through secreted interleukin-6. Kawada M; Ishizuka M; Takeuchi T Jpn J Cancer Res; 1999 May; 90(5):546-54. PubMed ID: 10391095 [TBL] [Abstract][Full Text] [Related]
18. Estrogens affect endothelin-1 mRNA expression in LNCaP human prostate carcinoma cells. Grande M; Carlström K; Stege R; Pousette A; Faxén M Eur Urol; 2002 May; 41(5):568-72; discussion 573-4. PubMed ID: 12074801 [TBL] [Abstract][Full Text] [Related]
19. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791 [TBL] [Abstract][Full Text] [Related]
20. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]